|
[1] ASRANI SK,DEVARBHAVI H,EATON J,et al. Burden of liver diseases in the world[J]. J Hepatol,2019,70(1):151-171.
|
|
[2] OECD. Obesity Update[EB/OL]. https://www. oecd. org/els/health-systems/Obesity-Update-2017. pdf. Accessed August 1,2019.
|
|
[3] LI J,ZOU B,YEO YH,et al. Prevalence,incidence,and outcome of non-alcoholic fatty liver disease in Asia,1999-2019:A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2019,4(5):389-398.
|
|
[4] World Health Organization. Global status report on alcohol and health 2018[EB/OL]. https://www. who. int/substance_abuse/publications/global_alcohol_report/gsr_2018. en/．Accessed August 1,2019.
|
|
[5] SHIELD KD,RYLETT M,REHM J. Public health successes and missed opportunities. Trends in alcohol consumption and attributable mortality in the WHO European Region,1990-2014(2016)[EB/OL]. http://www. euro. who. int/en/home.
|
|
[6] SINGAL AK,BATALLER R,AHN J,et al. ACG clinical guideline:Alcoholic liver disease[J]. Am J Gastroenterol,2018,113(2):175-194.
|
|
[7] CAO HX,FAN JG. Alcoholic fatty liver disease with nonalcoholic fatty liver disease and obesity[J]. J Clin Hepatol,2019,35(3):478-480.(in Chinese)曹海霞，范建高．酒精性肝病合并非酒精性脂肪性肝病和肥胖[J]．临床肝胆病杂志，2019,35(3):478-480.
|
|
[8] SINGH A,AMIN H,GARG R,et al. Increased prevalence of obesity and metabolic syndrome in patients with alcoholic fatty liver disease[J]. Dig Dis Sci,2020.[Online Ahead of Print]
|
|
[9] YAMADA K,MIZUKOSHI E,SEIKE T,et al. Light alcohol consumption has the potential to suppress hepatocellular injury and liver fibrosis in non-alcoholic fatty liver disease[J]. PLo S One,2018,13(1):e0191026.
|
|
[10] BELLENTANI S,SACCOCCIO G,MASUTTI F,et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy[J]. Ann Intern Med,2000,132(2):112-117.
|
|
[11] FAZZINO TL,FLEMING K,SHER KJ,et al. Heavy drinking in young adulthood increases risk of transitioning to obesity[J].Am J Prev Med,2017,53(2):169-175.
|
|
[12] LOOMBA R,BETTENCOURT R,BARRETT-CONNOR E. Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults:The Rancho Bernardo Study[J]. Aliment Pharmacol Ther,2009,30(11-12):1137-1149.
|
|
[13]BERG F,HELENIUS-HIETALA J,PUUKKA P,et al. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population[J]. Hepatology,2018,67(6):2141-2149.
|
|
[14]BERG F,FRKKILM,MNNISTV. Interaction between alcohol use and metabolic risk factors for liver disease:A critical review of epidemiological studies[J]. Alcohol Clin Exp Res,2020,44(2):384-403.
|
|
[15] YOUNOSSI ZM,STEPANOVA M,ONG J,et al. Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease[J]. Clin Gastroenterol Hepatol,2019,17(8):1625-1633. e1.
|
|
[16] DULY AM,ALANI B,HUANG EY,et al. Effect of multiple binge alcohol on diet-induced liver injury in a mouse model of obesity[J]. Nutr Diabetes,2015,5:e154.
|
|
[17]BERG F,PUUKKA P,SAHLMAN P,et al. Metabolic risk factors for severe liver disease among alcohol risk users in the general population[J]. J Hepatol,2019,70(Suppl):e273.
|
|
[18]BERG F,PUUKKA P,SALOMAA V,et al. Risks of light and moderate alcohol use in fatty liver disease:Follow-up of population cohorts[J]. Hepatology,2020,71(3):835-848.
|
|
[19] SAHLMAN P,NISSINEN M,PUUKKA P,et al. Genetic and lifestyle risk factors for advanced liver disease among men and women[J]. J Gastroenterol Hepatol,2020,35(2):291-298.
|
|
[20] BAECKER A,LIU X,LA VECCHIA C,et al. Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors[J]. Eur J Cancer Prev,2018,27(3):205-212.
|
|
[21] FORD ES,GILES WH,DIETZ WH. Prevalence of the metabolic syndrome among US adults:Findings from the third National Health and Nutrition Examination Survey[J]. JAMA,2002,287(3):356-359.
|
|
[22] BOYLE M,MASSON S,ANSTEE QM. The bidirectional impacts of alcohol consumption and the metabolic syndrome:Cofactors for progressive fatty liver disease[J]. J Hepatol,2018,68(2):251-267.
|
|
[23] LONGATO L,RIPP K,SETSHEDI M,et al. Insulin resistance,ceramide accumulation,and endoplasmic reticulum stress in human chronic alcohol-related liver disease[J]. Oxid Med Cell Longev,2012,2012:479348.
|
|
[24] NAVEAU S,GIRAUD V,BOROTTO E,et al. Excess weight risk factor for alcoholic liver disease[J]. Hepatology,1997,25(1):108-111.
|
|
[25] TESCHKE R. Alcoholic liver disease:Alcohol metabolism,cascade of molecular mechanisms,cellular targets,and clinical aspects[J]. Biomedicines,2018,6(4):106.
|
|
[26] MIYAKE T,KUMAGI T,HIROOKA M,et al. Low alcohol consumption increases the risk of impaired glucose tolerance in patients with non-alcoholic fatty liver disease[J]. J Gastroenterol,2016,51(11):1090-1100.
|
|
[27]BERG F,FRKKILM. Drinking and obesity:Alcoholic liver disease/nonalcoholic fatty liver disease interactions[J]. Semin Liver Dis,2020,40(2):154-162.
|
|
[28] MAHLI A,HELLERBRAND C. Alcohol and obesity:A dangerous association for fatty liver disease[J]. Dig Dis,2016,34Suppl 1:32-39.
|
|
[29] ALBILLOS A,GOTTARDI A,RESCIGNO M. The gut-liver axis in liver disease:Pathophysiological basis for therapy[J]. J Hepatol,2020,72(3):558-577.
|
|
[30] PARKER R,KIM SJ,GAO B. Alcohol,adipose tissue and liver disease:Mechanistic links and clinical considerations[J]. Nat Rev Gastroenterol Hepatol,2018,15(1):50-59.
|
|
[31] LOSURDO G,CASTELLANETA A,RENDINA M,et al. Systematic review with meta-analysis:De novo non-alcoholic fatty liver disease in liver-transplanted patients[J]. Aliment Pharmacol Ther,2018,47(6):704-714.
|
|
[32] KRAWCZYK M,LIEBE R,LAMMERT F,et al. Towards genetic prediction of non-alcoholic fatty liver disease trajectories:PNPLA3 and beyond[J]. Gastroenterology,2020,158(7):1865-1880.
|
|
[33] RAUSCH V,MUELLER S. Suppressed fat mobilization due to PNPLA3 rs738409-associated liver damage in heavy drinkers:The liver damage feedback hypothesis[J]. Adv Exp Med Biol,2018,1032:153-172.
|
|
[34] BIBBS,IANIRO G,DORE MP,et al. Gut microbiota as a driver of inflammation in nonalcoholic fatty liver disease[J].Mediators Inflamm,2018,2018:9321643.
|
|
[35] LITWINOWICZ K,CHOROSZY M,WASZCZUK E. Changes in the composition of the human intestinal microbiome in alcohol use disorder:A systematic review[J]. Am J Drug Alcohol Abuse,2020,46(1):4-12.
|
|
[36]BERG F,PUUKKA P,SALOMAA V,et al. Combined effects of alcohol and metabolic disorders in patients with chronic liver disease[J]. Clin Gastroenterol Hepatol,2020,18(4):995-997. e2.
|
|
[37] ESLAM M,NEWSOME PN,SARIN SK,et al. A new definition for metabolic dysfunction-associated fatty liver disease:An international expert consensus statement[J]. J Hepatol,2020,73(1):202-209.
|
|
[38] ESLAM M,SANYAL AJ,GEORGE J,et al. MAFLD:A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology,2020,158(7):1999-2014. e1.
|
DownLoad: